Ceregene Overview

  • Founded
  • 2000

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 30

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.71M

Ceregene General Information

Description

Developer of treatments for neurodegenerative disorders. The company is a biotechnology enterprise ocused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Its clinical programs include CERE-110, an AAV2-based vector expressing nerve growth factor, for the treatment of Alzheimer's disease; and CERE-120, in trials as a treatment for Parkinson's disease. The company also has two treatments - CERE-135 and CERE-140 - in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Primary Office
  • 9381 Judicial Drive
  • Suite 130
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ceregene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 02-Oct-2013 $2.71M 000.00 00.000 Completed Clinical Trials - Phase 2
7. Later Stage VC 03-Apr-2012 000.00 Completed Generating Revenue
6. Later Stage VC (Series D) 11-Nov-2010 000.00 000.00 Completed Generating Revenue
5. Grant 22-Jun-2010 00.00 000.00 Completed Generating Revenue
4. Grant 01-Jan-2008 00.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 22-Jun-2007 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 13-Aug-2004 $19.7M $30.2M Completed Startup
1. Early Stage VC (Series A) 01-Jan-2001 $10.5M $10.5M Completed Startup
To view Ceregene’s complete valuation and funding history, request access »

Ceregene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of treatments for neurodegenerative disorders. The company is a biotechnology enterprise ocused on the treatme
Biotechnology
San Diego, CA
30 As of 2017
000.00
0.000 0000-00-00
000000&0 000.00

000000

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000 000000000
Boston, MA
0000 As of 0000
00.000
000 0000-00-00
000000&0

000000

or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariat
0000 000000000
Framingham, MA
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ceregene Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vertex Pharmaceuticals Formerly VC-backed Boston, MA 0000 00.000 000000&0
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
000000 00000000000 Corporation New York, NY 00 00000 000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 Venture Capital-Backed Paris, France 00 0000 00000000000 0000
You’re viewing 5 of 43 competitors. Get the full list »

Ceregene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ceregene Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alta Partners Venture Capital Minority 000 0000 000000 0
California Technology Ventures Venture Capital Minority 000 0000 000000 0
Cell Genesys Corporation Minority 000 0000 000000 0
Hamilton BioVentures Venture Capital Minority 000 0000 000000 0
MPM Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ceregene Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000-000 0000 09-Mar-2009 0000000000 Other Commercial Services
To view Ceregene’s complete acquisitions history, request access »